Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe. Oral gamma secretase inhibitor Ogsiveo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback